Piper Sandler initiated coverage of Merus (MRUS) with an Overweight rating and $84 price target The firm views the company’s EGFRxLGR5 bispecific, petosemtamab, as “significantly de-risked ...

The new Meru Governor Isaac Mutuma M'Ethingia took the oath of office on Monday, replacing the impeached Kawira Mwangaza who ...

Merus N.V. announced progress on its clinical trials involving petosemtamab, designed for treating recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal ...

MRUS opened at $47.58 on Monday. Merus has a 52-week low of $37.77 and a 52-week high of $61.61. The firm has a market capitalization of $3.29 billion, a PE ratio of -12.05 and a beta of 1.15. The ...